Table 3.
Univariate analyses of survival outcomes by patient and treatment-related factors
| Overall Survival, HR (95 % CI) | Time to loco-regional recurrence, mos (95 % CI) | Time to distant metastases, mos (95 % CI) | |
|---|---|---|---|
| LRR vs. NP SCCHN | 0.84 (0.49–1.49) | 1.05 (0.51–2.38) | 0.99 (0.58–1.77) |
| P = 0.53 | P = 0.91 | P = 0.96 | |
| Age at diagnosis of LRR/NP SCCHN | 1.4 (0.84–2.36) | 1.01 (0.52–2.03) | 1.62 (0.97–2.77) |
| < 60 vs. ≥ 60 | P = 0.2 | P = 0.97 | P = 0.07 |
| Sex | 0.92 (0.52–1.71) | 0.53 (0.27–1.15) | 0.98 (0.54–1.91) |
| Male vs. Female | P = 0.78 | P = 0.1 | P = 0.95 |
| Tobacco abuse | 0.67 (0.86–2.72) | 1.84 (0.26–1.12) | 0.82 (0.71–2.16) |
| < 20 PY vs. > 20 PY | P = 0.16 | P = 0.1 | P = 0.48 |
| Post-operative vs. Definitive RRT | 0.67 (0.4–1.11) | 0.62 (0.31–1.23) | 0.67 (0.4–1.1) |
| P = 0.12 | P = 0.17 | P = 0.12 | |
| Time since primary SCCHN | 0.77 (0.44–1.3) | 1.19 (0.43–1.73) | 0.79 (0.75–2.18) |
| < 24 mos vs. ≥ 24 mos | P = 0.33 | P = 0.63 | P = 0.39 |
| Chemotherapy vs. no chemotherapy with RRT | 1.47 (0.82–2.84) | 2.43 (1.02–7.16) | 1.12 (0.66–1.98) |
| P = 0.2 | P = 0.04 | P = 0.68 | |
| Platinum vs. cetuximab with RRT | 0.65 (0.36–1.22) | 0.4 (0.19–0.86) | 0.65 (0.33–1.31) |
| P = 0.18 | P = 0.02 | P = 0.22 | |
| IMRT versus other | 0.99 (0.4–3.32) | 2.03 (0.43–36.2) | 1.21 (0.49–4.04) |
| P = 0.99 | P = 0.44 | P = 0.71 |
CI confidence interval, HR hazard ratio, IMRT intensity modulated radiation therapy, LRR loco-regionally recurrent, NP new primary, NR not reached, PY pack-years, RRT reirradiation therapy, SCCHN squamous cell carcinoma of head and neck